Circulating Vitamin D, Supplement Use, and Cardiovascular Disease Risk: The MrOS Sleep Study

The Journal of Clinical Endocrinology and Metabolism (Impact Factor: 6.21). 03/2014; 99(9):jc20134178. DOI: 10.1210/jc.2013-4178
Source: PubMed


Context: Evidence suggests an inverse association between circulating 25(OH) vitamin D and cardiovascular disease (CVD). Objective: Determine the association between serum 25(OH) vitamin D and risk for CVD events. Design: From March 2000 to April 2002, participants were recruited for the Osteoporotic Fractures in Men (MrOS) study; between December 2003 and March 2005, members of the MrOS cohort were invited to participate in the MrOS Sleep Study. We followed participants from the sleep study cohort for a mean of 5.9 years. Setting: Clinical centers at six recruitment sites across the United States. Patients: 3,135 men aged 65 and older from the MrOS cohort, of whom 116 were excluded for missing vitamin D or CVD data. Interventions: Participants were divided into two groups based on serum 25(OH) vitamin D levels: <20 ng/mL and ≥20 ng/mL. Main Outcome Measure: Participants were followed for CVD endpoints: coronary heart disease (CHD) and cerebrovascular events. We calculated age- and multivariable adjusted hazard ratios and stratified by use of vitamin D containing supplements. Results: We observed no significant association between circulating 25(OH) vitamin D and risk of CVD event (HR=0.91, 95% CI=0.73-1.13) and CHD event (HR=0.81, 95% CI=0.61-1.07). For cerebrovascular events, men with vitamin D deficiency appeared to exhibit a higher risk (HR=1.44, 95% CI=1.00-2.08) using the minimally adjusted model and after excluding supplement users (HR=1.70, 95% CI=1.02-2.83). Conclusions: 25(OH) vitamin D was not associated with risk of CVD and CHD events. However, vitamin D deficiency may be associated with an increased risk of cerebrovascular events.

31 Reads


31 Reads
Available from